Magpie Diagnostics
Prostate

Prostate Cancer: An Overview

What prostate is, how common it is, how it's found, and how diagnosis and treatment are guided.

✓ Medically reviewedMarch 21, 20265 min read
Share

What it is

Prostate cancer is a malignancy arising in the prostate, a walnut-sized gland that sits below the bladder and surrounds the urethra in men. The overwhelming majority of cases are acinar adenocarcinoma, a cancer of the gland-forming epithelial cells. Less common but clinically important variants include intraductal carcinoma of the prostate (IDC-P) [4][5] and neuroendocrine/small cell carcinoma, the latter sometimes emerging after prolonged hormonal therapy ("treatment-emergent") [6]. These distinctions matter because they behave differently and are recognized through specific tissue and marker patterns, discussed below.

A defining feature of prostate cancer is its enormous biological range. Many tumors are slow-growing and may never threaten a man's health during his lifetime, while a minority are aggressive and capable of spreading early [7]. Much of modern prostate cancer care is devoted to telling these apart.

How common it is

Prostate cancer is the most commonly diagnosed cancer in men. The American Cancer Society projects approximately 333,830 new U.S. cases for 2026, making it the leading cancer diagnosis in men and roughly 15.8% of all new cancer diagnoses [2]. The age-adjusted incidence rate is 123.2 per 100,000 men per year (2019, 2023) [1], and a man's lifetime risk of being diagnosed is about 13.2%, or roughly 1 in 8 [1].

Incidence has been rising by about 2.9% per year, and, importantly, this includes a notable increase in regional- and distant-stage disease at diagnosis [1]. The evidence suggests this stage shift is attributable in part to changes in screening practices over the past decade, a contested and actively studied area. Mortality is far lower than incidence: an estimated 36,320 U.S. deaths are projected for 2026 [2], with a mortality rate of 18.9 per 100,000 men per year (2020, 2024) [1].

Who's at risk

Most established risk factors are not modifiable:

  • Age. Prostate cancer is rare before 40 and most frequently diagnosed between ages 65 and 74 [1].
  • Race/ethnicity. Non-Hispanic Black men experience higher incidence and higher mortality [1]. The reasons are multifactorial and include biological, social, and access-related dimensions.
  • Family history and inherited genetics. A first-degree family history raises risk. Germline BRCA2 and certain other homologous-recombination-repair (HRR) and Lynch syndrome alterations are associated with increased risk; their independent effect on disease aggressiveness and outcome is reported but remains contested in the diagnostic literature [8][9][10][11][12].
  • Genetic ancestry. Inherited risk variants contribute to baseline susceptibility [1].

The provided data do not establish well-defined modifiable risk factors for prostate cancer; accordingly, none are claimed here.

How it's found

Most prostate cancer today is asymptomatic and screen-detected. When symptoms do occur, they are usually from advanced disease, urinary symptoms or, in metastatic cases, bone pain.

The main screening tools are:

  • PSA (prostate-specific antigen) blood test, the primary screening modality.
  • Digital rectal exam (DRE), used as an adjunct.
  • MRI and reflex biomarker testing, increasingly incorporated into evolving diagnostic pathways.

On screening guidance, the U.S. Preventive Services Task Force (USPSTF, 2018) frames PSA screening as an individualized, shared decision for men aged 55, 69 (grade C), meaning the decision should reflect a man's values and his discussion with a clinician. The USPSTF recommends against routine PSA screening at age 70 and older, and earlier discussion may be appropriate for higher-risk groups [3]. This guidance is presented neutrally and is not a recommendation to any individual reader.

A central reason for the individualized framing is a documented benefit, harm tradeoff: PSA screening can detect lethal cancers earlier but also leads to overdiagnosis of indolent disease that might never have caused harm. Partly in response, active surveillance, careful monitoring rather than immediate treatment, has become standard for many low-risk cancers.

Outlook

Prostate cancer has one of the highest survival rates among major cancers. Based on SEER data (2016, 2022 survival), the overall 5-year relative survival is about 98% [1]. By stage at diagnosis:

  • Localized or regional disease: greater than 99% 5-year relative survival [1].
  • Distant (metastatic) disease: approximately 38% [1].

About 69.5% of cases are diagnosed at a local stage [1], which helps explain the high overall survival, while showing why the rising share of distant-stage disease is concerning.

These figures are population statistics, not individual predictions. A relative survival percentage describes how a large group of diagnosed men fared compared with the general population; it cannot tell any single person how he will do. Individual outcomes depend on tumor grade, extent, genetics, overall health, treatment, and factors not captured in these averages. They should never be read as a personal prognosis.

How it's diagnosed and classified, a bridge

Diagnosis rests on tissue: a biopsy is examined to confirm adenocarcinoma and to assign an ISUP Grade Group (derived from Gleason architecture), the single most influential descriptor of how aggressive a tumor is likely to be [7][13][14]. Pathologists use a **diagnostic immunohistochemistry triad, basal cell markers, AMACR, and NKX3.1, **to distinguish cancer from benign mimics [15][16][17], and they specifically look for higher-risk patterns such as IDC-P [4][5] or neuroendocrine differentiation [6]. These classification axes are explored in detail in the diagnosis pillar.

How treatment is guided, a bridge

Treatment selection is increasingly informed by molecular biomarkers that define eligibility for specific drug classes, not by any single rule. For example, germline or somatic HRR alterations (such as BRCA2) [18], mismatch-repair deficiency/MSI-high status [19][20][21], PTEN loss [22][23], and PSMA expression (a theranostic target) [24][25] each map to distinct therapeutic strategies under investigation or in use. A related lineage biomarker, the TMPRSS2::ERG fusion detectable by ERG immunohistochemistry, is also used in this diagnostic workup [26][27]. These are population-level eligibility concepts and are addressed in the biomarker and therapy pillars; nothing here constitutes treatment advice for an individual.

References

  1. National Cancer Institute. SEER Cancer Stat Facts (SEER*Explorer). 2026 release (2019, 2023 incidence; 2020, 2024 mortality; 2016, 2022 survival). seer.cancer.gov/statfacts.

  2. Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026. doi:10.3322/caac.70043.

  3. US Preventive Services Task Force. Prostate Cancer: Screening (2018 Recommendation). 2018. uspreventiveservicestaskforce.org.

  4. Böttcher R, et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer. 2018. PMID 29295717.

  5. Schweizer MT, et al. Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. JCO Precis Oncol. 2019. PMID 31123724.

  6. Beltran H, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016. PMID 26855148. doi:10.1038/nm.4045.

  7. Epstein JI, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score (ISUP Grade Groups). Eur Urol. 2016. PMID 26166626.

  8. Castro E, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013. PMID 23569316.

  9. Wei Y, et al. Germline DNA repair gene mutations and clinical outcomes in metastatic castration-sensitive prostate cancer. Oncologist. 2020. PMID 32190957.

  10. Stopsack KH, et al. Germline DNA damage repair gene alterations and prognosis in prostate cancer. Clin Cancer Res. 2025. PMID 39450704.

  11. Risbridger GP, et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a BRCA2-associated, survival-relevant lesion. Eur Urol. 2015. PMID 25154392.

  12. Isaacsson Velho P, et al. Intraductal/ductal histology and germline DNA-repair alterations in prostate cancer. Prostate. 2018. PMID 29368341.

  13. van Leenders GJLH, et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2019. PMID 32459716. doi:10.1097/PAS.0000000000001497.

  14. Okubo Y, et al. ISUP Grade Groups and clinicopathologic parameters in prostate cancer. Front Oncol. 2021. PMID 34395260. doi:10.3389/fonc.2021.695251.

  15. Ali TZ, Epstein JI. False-positive labeling of prostate cancer basal cells: p63 and high-molecular-weight cytokeratin. Am J Surg Pathol. 2008. PMID 18813120. doi:10.1097/PAS.0b013e31817ce994.

  16. Jiang Z, et al. P504S/AMACR in the detection of small foci of prostatic adenocarcinoma. Am J Surg Pathol. 2002. PMID 12218573. doi:10.1097/00000478-200209000-00007.

  17. Gurel B, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010. PMID 20588175. doi:10.1097/PAS.0b013e3181e6cbf3.

  18. de Bono J, et al. Olaparib for metastatic castration-resistant prostate cancer (PROfound). N Engl J Med. 2020. PMID 32343890. doi:10.1056/NEJMoa1911440.

  19. Abida W, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019. PMID 30589920. doi:10.1001/jamaoncol.2018.5801.

  20. Middha S, et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data (MSIsensor). JCO Precis Oncol. 2017. PMID 30211344.

  21. Hempelmann JA, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J Immunother Cancer. 2018. PMID 29665853.

  22. Fizazi K, et al. Capivasertib in PTEN-deficient metastatic hormone-sensitive prostate cancer (CAPItello-281). Ann Oncol. 2026. PMID 41120017.

  23. Lotan TL, et al. PTEN loss detection in prostate cancer: comparison of IHC and FISH. Oncotarget. 2017. PMID 29029453. doi:10.18632/oncotarget.19217.

  24. Sartor O, et al. Lutetium-177, PSMA-617 for metastatic castration-resistant prostate cancer (VISION). N Engl J Med. 2021. PMID 34161051. doi:10.1056/NEJMoa2107322.

  25. Hofman MS, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before definitive therapy (proPSMA). Lancet. 2020. PMID 32209449. doi:10.1016/S0140-6736(20)30314-7.

  26. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015. PMID 26544944.

  27. Park K, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010. PMID 20651988. doi:10.1593/neo.10726.

Tags

overviewepidemiologyscreening